HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

T Kasahara Selected Research

Neoplasms (Cancer)

9/2005Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression.
8/2001Frequency of PSA-mRNA-bearing cells in the peripheral blood of patients after prostate biopsy.
6/2001Antitumor effect of beta2-microglobulin in leukemic cell-bearing mice via apoptosis-inducing activity: activation of caspase-3 and nuclear factor-kappaB.
7/2000Caspase involved synergistic cytotoxicity of bcl-2 antisense oligonucleotides and adriamycin on transitional cell cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


T Kasahara Research Topics

Disease

4Neoplasms (Cancer)
09/2005 - 07/2000
2Mitochondrial Diseases (Mitochondrial Disease)
01/2016 - 06/2006
2Glioblastoma (Glioblastoma Multiforme)
04/2001 - 03/2001
1Disease Progression
04/2019
1Prostatic Neoplasms (Prostate Cancer)
04/2019
1Non-alcoholic Fatty Liver Disease
10/2010
1Cardiovascular Diseases (Cardiovascular Disease)
10/2010
1Pheochromocytoma
02/2010
1Mood Disorders (Mood Disorder)
06/2006
1Bipolar Disorder (Manic Depressive Psychosis)
06/2006
1Mania (Manias)
06/2006
1Chronic Progressive External Ophthalmoplegia (Progressive External Ophthalmoplegia)
06/2006
1Carcinogenesis
09/2005
1Cataract (Cataracts)
12/2003
1Gangrene
12/2003
1Osteomyelitis
12/2003
1Nephrotic Syndrome (Syndrome, Nephrotic)
08/2001
1Proteinuria
08/2001
1Hematuria
08/2001
1Leukemia
06/2001
1Glioma (Gliomas)
02/2001
1Herpes Zoster
01/2001
1Malocclusion (Crossbite)
01/2000
1Pathologic Constriction (Stenosis)
01/2000

Drug/Important Bio-Agent (IBA)

3NF-kappa B (NF-kB)IBA
06/2001 - 03/2001
2Mitochondrial DNA (mtDNA)IBA
01/2016 - 06/2006
1Eicosapentaenoic AcidIBA
10/2010
1Triglycerides (Triacylglycerol)IBA
10/2010
1Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA
10/2010
1AcidsIBA
10/2010
1Peptides (Polypeptides)IBA
02/2010
1urotensin IIIBA
02/2010
1LithiumIBA
06/2006
1Antidepressive Agents (Antidepressants)IBA
06/2006
1Tricyclic Antidepressive Agents (Tricyclic Antidepressants)IBA
06/2006
1Fas Ligand Protein (Fas Ligand)IBA
09/2005
1Death Domain ReceptorsIBA
09/2005
1Messenger RNA (mRNA)IBA
08/2001
1CreatinineIBA
08/2001
1Complement System Proteins (Complement)IBA
08/2001
1AntibodiesIBA
06/2001
1Caspase 3 (Caspase-3)IBA
06/2001
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2001
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
04/2001
12- (2- amino- 3- methoxyphenyl)- 4H- 1- benzopyran- 4- oneIBA
04/2001
12- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA
03/2001
1Phosphotransferases (Kinase)IBA
03/2001
1Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA
03/2001
1p38 Mitogen-Activated Protein KinasesIBA
03/2001
1SB 203580IBA
03/2001
1Caspase 6IBA
02/2001
1Immunosuppressive Agents (Immunosuppressants)IBA
02/2001
1Fingolimod Hydrochloride (FTY720)FDA Link
02/2001
1Proteins (Proteins, Gene)FDA Link
01/2001
1Doxorubicin (Adriamycin)FDA LinkGeneric
07/2000
1Antisense OligonucleotidesIBA
07/2000
1CaspasesIBA
07/2000

Therapy/Procedure

1Radiotherapy
04/2019
1Brachytherapy
04/2019
1Surgical Amputation (Amputations)
12/2003
1Therapeutics
06/2001
1Stents
01/2000
1Sutures (Suture)
01/2000